Relay Therapeutics (RLAY) News Today $2.91 +0.06 (+2.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.90 -0.01 (-0.17%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Northern Trust Corp lifted its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 24.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,169,979 shares of the compMay 24 at 3:18 AM | marketbeat.comBNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)BNP Paribas Financial Markets acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 239,668 shares of the company's stMay 23 at 3:17 AM | marketbeat.comPoint72 Asset Management L.P. Raises Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Point72 Asset Management L.P. raised its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 18.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,592,753 shares of the company's stockMay 22 at 4:41 AM | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) is Tang Capital Management LLC's 9th Largest PositionTang Capital Management LLC lifted its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 126.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,068,058 shares of the company's stock after purchasing anMay 20, 2025 | marketbeat.com180,000 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Raiffeisen Bank International AGRaiffeisen Bank International AG bought a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 180,000 shares of the company's stock, valued at approximately $752May 19, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives $17.67 Consensus Target Price from BrokeragesMay 19, 2025 | americanbankingnews.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twelve ratings firms that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and ten have issued aMay 18, 2025 | marketbeat.comMPM Bioimpact LLC Has $9.35 Million Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)MPM Bioimpact LLC raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,268,825 shares of the company's stock after acquiring an additional 235,784 sharMay 16, 2025 | marketbeat.comParkman Healthcare Partners LLC Takes $2.06 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Parkman Healthcare Partners LLC purchased a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 500,548 shares of the company's stockMay 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 48.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330,699 shMay 16, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)May 15, 2025 | theglobeandmail.com692,279 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Bought by Balyasny Asset Management L.P.Balyasny Asset Management L.P. acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 692,279 shares of the company's stock, vaMay 14, 2025 | marketbeat.comRelay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comHC Wainwright Issues Optimistic Forecast for RLAY EarningsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 EPS estimates for Relay Therapeutics in a research note issued to investors on Wednesday, May 7th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0May 13, 2025 | marketbeat.com89,949 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by First Trust Advisors LPFirst Trust Advisors LP acquired a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 89,949 shares of the company's stock, valued at approximately $371,000.May 12, 2025 | marketbeat.comDimensional Fund Advisors LP Grows Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Dimensional Fund Advisors LP increased its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 69.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,964,997 shares of the company's stock after bMay 12, 2025 | marketbeat.comVoya Investment Management LLC Has $667,000 Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)Voya Investment Management LLC increased its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 392.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 161,827 shares of the company's stock afterMay 11, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic Outlook of RLAY Q2 EarningsRelay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Equities researchers at Leerink Partnrs reduced their Q2 2025 EPS estimates for shares of Relay Therapeutics in a research report issued on Monday, May 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earningsMay 10, 2025 | marketbeat.comAlgert Global LLC Buys 481,646 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Algert Global LLC raised its stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 93.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 994,923 shares of the company's stock after acquiring an additional 481,646 sharesMay 9, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Takes $1.46 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Schonfeld Strategic Advisors LLC acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 354,500May 9, 2025 | marketbeat.comMarshall Wace LLP Lowers Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Marshall Wace LLP lowered its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 98.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,768 shares of the company's stock after selling 1,377,946 sharMay 9, 2025 | marketbeat.comRaymond James Financial Inc. Takes $779,000 Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Raymond James Financial Inc. acquired a new stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 189,046 shares of the company's stock, valued at approximately $779,000. Raymond James FiMay 9, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) is Casdin Capital LLC's 9th Largest PositionCasdin Capital LLC reduced its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 8,948,574 shares of the company's stock after selling 302,534 shares during thMay 8, 2025 | marketbeat.comRelay Therapeutics Extends Cash Runway into 2029 Amid Clinical Trial AdvancementsMay 7, 2025 | nasdaq.comRelay Therapeutics, Inc. (RLAY): A Bull Case TheoryMay 7, 2025 | insidermonkey.comRelay Therapeutics (NASDAQ:RLAY) Issues Quarterly Earnings ResultsRelay Therapeutics (NASDAQ:RLAY - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.51) by $0.05.May 7, 2025 | marketbeat.comRelay Therapeutics, Inc.: Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate UpdatesMay 6, 2025 | finanznachrichten.deRelay Therapeutics Reports First Quarter 2025 Financial Results and Corporate UpdatesMay 5, 2025 | globenewswire.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by Price T Rowe Associates Inc. MDPrice T Rowe Associates Inc. MD lowered its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 37.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,321,741 shares of the company's stock after sMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Acquires Shares of 536,132 Relay Therapeutics, Inc. (NASDAQ:RLAY)Boxer Capital Management LLC bought a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 536,132 shares of the company's stock, valuMay 4, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Buys New Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Susquehanna Fundamental Investments LLC purchased a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 346,288 shares ofMay 4, 2025 | marketbeat.comRelay Therapeutics Q1 2025 Earnings PreviewMay 3, 2025 | msn.comRelay Therapeutics (NASDAQ:RLAY) Shares Down 5.4% - What's Next?Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4% - Should You Sell?May 1, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Sells 10,739 Shares of StockMay 1, 2025 | insidertrades.comAdage Capital Partners GP L.L.C. Sells 250,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Adage Capital Partners GP L.L.C. decreased its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 15.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,400,000 shares of the company's stock after selling 250,000 shares during theMay 1, 2025 | marketbeat.comRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025April 28, 2025 | globenewswire.comRelay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on ThursdayRelay Therapeutics (NASDAQ:RLAY) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-relay-therapeutics-inc-stock/)April 26, 2025 | marketbeat.comInsider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 61,422 Shares of StockApril 25, 2025 | insidertrades.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by Geode Capital Management LLCGeode Capital Management LLC grew its position in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 10.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,030,157 shares of the company's stock afterApril 23, 2025 | marketbeat.comRelay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buyApril 22, 2025 | marketbeat.comRenaissance Technologies LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)Renaissance Technologies LLC grew its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 130.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,549,190 shares of the cApril 21, 2025 | marketbeat.comFranklin Resources Inc. Sells 1,338,037 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Franklin Resources Inc. lessened its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 95.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,805 shares of the company's stock aftApril 21, 2025 | marketbeat.comRelay Therapeutics (RLAY): The Most Promising Penny Stock According to AnalystsApril 20, 2025 | insidermonkey.comRelay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at Wells Fargo & CompanyWells Fargo & Company assumed coverage on Relay Therapeutics in a research report on Thursday. They issued an "equal weight" rating and a $4.00 price objective on the stock.April 19, 2025 | marketbeat.comWalleye Capital LLC Has $3.82 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)Walleye Capital LLC decreased its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 49.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 927,137 shares of the company's stock after selling 892,846 shares dApril 19, 2025 | marketbeat.comWells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight RecommendationApril 18, 2025 | msn.comRelay Therapeutics initiated with an Equal Weight at Wells FargoApril 17, 2025 | markets.businessinsider.comIs Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | msn.comVanguard Group Inc. Acquires 566,595 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)Vanguard Group Inc. increased its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,030,209 shares of the company's stockApril 14, 2025 | marketbeat.comJPMorgan Chase & Co. Has $20.51 Million Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)JPMorgan Chase & Co. reduced its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 9.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,978,443 shares of the company's stock afApril 13, 2025 | marketbeat.com Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Media Mentions By Week RLAY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLAY News Sentiment▼1.260.75▲Average Medical News Sentiment RLAY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLAY Articles This Week▼65▲RLAY Articles Average Week Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KYMR News KNSA News CGON News TARS News GLPG News APGE News RXRX News TWST News BEAM News ARQT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLAY) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
